Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $463.86. The company's market cap stands at 117.75B, with a P/E ratio of 32.69.
As of 2026-01-11, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $463.42 and $475.33. The current price stands at $463.86, placing the stock +0.1% above today's low and -2.4% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 1.69M, compared to an average daily volume of 1.18M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Key Points Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens in 2026, though, Vert...
The latest trading session saw Vertex Pharmaceuticals (VRTX) ending at $503.20, denoting a -1.37% adjustment from its last day's close. The stock's change was l...
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Vertex Pharmaceuticals...
Analyst ratings
67%
of 36 ratingsMore VRTX News
If you are wondering whether Vertex Pharmaceuticals at around US$468 per share looks reasonably priced or stretched, you are not alone. The stock closed at US$...
UBS analyst Michael Yee assumed coverage of Vertex Pharmaceuticals (VRTX) with a Buy rating with a price target of $535, down from $546. The firm believes the r...
As previously reported, Wolfe Research analyst Andy Chen upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Peer Perform with a $548 price target. While...
Wolfe Research upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Peer Perform. Published first on TheFly – the ultimate source for real-time, market-mo...
Vertex Pharmaceuticals (VRTX) has been drawing attention after recent trading, with the stock around $452.13 and mixed short term returns. This has prompted inv...